(MENAFN – Khaleej Times)
Posted: Wed 13 Jul 2022, 01:20 PM
Kahn-Sagol-Maccabi (KSM), the research and innovation center of Israel’s Maccabi Healthcare Services, and healthcare organizations in the United Arab Emirates have signed a series of comprehensive strategic agreements to promote joint medical research and technological innovation.
According to the Abu Dhabi Media Office, the agreements were signed this week in Abu Dhabi, with Dr. Tal Patalon, Director of KSM; Ashish Ipe Koshy, CEO of G42 Health, a leading health technology company responsible for the Emirati Genome Program; and Saeed Al Kuwaiti, CEO of SEHA, the leading health organization in the United Arab Emirates. Amir Hayek, Israel’s Ambassador to the United Arab Emirates, and Aviad Tamir, Israel’s Economic Attaché in Abu Dhabi, also joined the signing ceremony.
This is notably the first agreement signed by SEHA with an Israeli organization. The SEHA-KSM partnership will also support the emirate’s goal of creating a genomic research registry to optimize clinical data, sample collection and clinical reporting.
The agreements relate to the promotion of medical research that combines the capabilities of big data with genetic and clinical research with the aim of advancing personalized medicine while emphasizing medical innovation and the establishment of a regional ecosystem that will support joint research activities. Studies will be conducted on cancer, cardiovascular disease, diabetes and more.
“This partnership supports SEHA’s vision and goals to explore opportunities for collaboration in other areas that promote cooperation in education, research, health technologies and clinical programs. We look forward to a successful partnership and the expansion of this program to our facilities and eminent practitioners,” said SEHA Group CEO Saeed Al Kuwaiti.
A joint study with G42 Health [AG2] is also already underway to examine the medical consequences of vitamin D deficiency. More than one billion people worldwide suffer from vitamin D deficiency, and this disease is common throughout the Middle East. The joint study will examine the impact of genetics on vitamin D metabolism that affects vitamin D status in Israeli and Emirati populations to better understand risk factors for deficiency.
“As the UAE and Israel continue to forge stronger ties, this collaboration comes at an opportune time as we join forces with an ambitious and committed partner like Kahn-Sagol-Maccabi (KSM). We are excited to shape a multitude of initiatives through research projects, clinical trials and to expand our CRO services to benefit universities, governments, healthcare entities and the general population in both countries, so that we are inventing better health care every day.
This further expands existing genetic research, a first of its kind, which aims to facilitate a preventive pharmacogenomic strategy for individuals based on understanding the genetic landscape of vitamin D deficiency in the United Arab Emirates and Israel,” commented Ashish Koshy. , CEO of G42 Healthcare.
The agreements with Abu Dhabi follow KSM’s recent collaboration with Bahrain’s Ministry of Health. KSM plans to sign other agreements with other countries in the future.
READ ALSO :
- United Arab Emirates: Patient with rare swallowing disorder undergoes life-changing procedure
- UAE doctors extract 7cm of kidney stones from 180kg man
“We continue to establish research collaborations with various countries in the region, implementing our vision of a shared innovative ecosystem that fosters research and development of advanced personalized medicine, while creating added value across the board. of the region,” said Dr Patalon.
“We are delighted and proud that another important step has been taken to promote relations between Israel and the United Arab Emirates,” added Ambassador Hayek, Israel’s Ambassador to the United Arab Emirates. “The field of medicine is of critical importance to both countries and such a partnership can improve the health of residents of our countries as well as the entire Middle East.”
Legal disclaimer: MENAFN provides the information “as is” without warranty of any kind. We assume no responsibility for the accuracy, content, images, videos, licensing, completeness, legality or reliability of any information in this article. If you have any complaints or copyright issues related to this article, please contact the provider above.